Literature DB >> 6629591

Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma.

R Obrist, R Reilly, T Leavitt, R C Knapp, R C Bast.   

Abstract

Availability of a chemically defined chemoattractant (fMLP) and of appropriate monoclonal antibodies may permit local manipulation of the inflammatory response to human tumors. fMLP has been conjugated with two monoclonal antibodies (OC125 and OC133) which react with human ovarian carcinomas. Conjugates retained the ability to bind to a human ovarian carcinoma line (OVCA433) judged by indirect immunofluorescence and by radioimmunoassay. The fMLP conjugate was maximally chemotactic for human blood monocytes and human peritoneal macrophages at protein concentrations of 300-900 micrograms/ml. Conjugates stimulated chemotaxis rather than chemokinesis. After incubation with an fMLP-antibody conjugate, antigen positive OVCA433 cells released chemotactic activity and attracted monocytes in vitro, whereas an antigen-negative ovarian cell line failed to do so. As monocytes can be important effectors of antibody dependent cell mediated cytoxicity, fMLP conjugates might increase monocyte concentrations at tumor sites and potentiate serotherapy for certain human neoplasms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6629591     DOI: 10.1016/0192-0561(83)90033-4

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  4 in total

Review 1.  HIV and the Macrophage: From Cell Reservoirs to Drug Delivery to Viral Eradication.

Authors:  Jonathan Herskovitz; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2018-03-23       Impact factor: 4.147

2.  Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: a phase I clinical trial.

Authors:  R Obrist; J Schmidli; R Müller; H Gallati; J P Obrecht
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Selective Display of a Chemoattractant Agonist on Cancer Cells Activates the Formyl Peptide Receptor 1 on Immune Cells.

Authors:  Eden L Sikorski; Janessa Wehr; Noel J Ferraro; Sophia M Rizzo; Marcos M Pires; Damien Thévenin
Journal:  Chembiochem       Date:  2022-03-09       Impact factor: 3.461

4.  Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation.

Authors:  Manuel Brehs; André J G Pötgens; Julia Steitz; Karine Thewes; Janett Schwarz; Anne C Conibear; Matthias Bartneck; Frank Tacke; Christian F W Becker
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.